# A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

> **NCT01604889** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 50 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Epacadostat
- **DRUG:** ipilimumab

## Key facts

- **NCT ID:** NCT01604889
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03-29
- **Primary completion:** 2016-12-27
- **Final completion:** 2017-01-20
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued.
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01604889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01604889, "A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01604889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*